You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Baclofen - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for baclofen and what is the scope of patent protection?

Baclofen is the generic ingredient in eight branded drugs marketed by Amneal, Heritage, Maia Pharms Inc, Mylan Labs Ltd, Rubicon, Piramal Critical, Metacel Pharms Llc, Ani Pharms, Azurity, Ucb Inc, Andas 5 Holding, Appco, Aurobindo Pharma Ltd, Beximco Pharms Usa, Endo Operations, Eywa, Graviti Pharms, Impax, Ivax Sub Teva Pharms, Lannett Co Inc, Mankind Pharma, Micro Labs, Northstar Hlthcare, Norvium Bioscience, Oxford Pharms, Rising, Sun Pharm Inds Inc, Teva, Unichem, Upsher Smith Labs, Usl Pharma, Watson Labs, Zydus Lifesciences, and Novartis, and is included in forty-eight NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baclofen has fourteen patent family members in eight countries.

There are twenty-one drug master file entries for baclofen. Sixty-five suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for baclofen

See drug prices for baclofen

Drug Sales Revenue Trends for baclofen

See drug sales revenues for baclofen

Recent Clinical Trials for baclofen

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospices Civils de LyonPhase 2/Phase 3
University of LouisvillePhase 2
Institute of Liver and Biliary Sciences, IndiaN/A

See all baclofen clinical trials

Generic filers with tentative approvals for BACLOFEN
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up5MG/5MLSOLUTION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for baclofen
Medical Subject Heading (MeSH) Categories for baclofen
Paragraph IV (Patent) Challenges for BACLOFEN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FLEQSUVY Oral Suspension baclofen 25 mg/5 mL 215602 1 2022-05-20
OZOBAX DS Oral Solution baclofen 5 mg/5 mL 208193 1 2021-07-26

US Patents and Regulatory Information for baclofen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Usl Pharma BACLOFEN baclofen TABLET;ORAL 071260-001 May 6, 1988 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Lifesciences BACLOFEN baclofen TABLET;ORAL 211659-003 Apr 17, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impax BACLOFEN baclofen TABLET;ORAL 077971-002 Oct 26, 2007 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan Labs Ltd BACLOFEN baclofen INJECTABLE;INTRATHECAL 209592-002 Mar 21, 2018 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Ltd BACLOFEN baclofen TABLET;ORAL 214099-002 Jul 13, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal LYVISPAH baclofen GRANULES;ORAL 215422-002 Nov 22, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Zydus Lifesciences BACLOFEN baclofen TABLET;ORAL 211659-001 Nov 23, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for baclofen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-001 Oct 30, 2003 ⤷  Sign Up ⤷  Sign Up
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-002 Oct 30, 2003 ⤷  Sign Up ⤷  Sign Up
Novartis LIORESAL baclofen TABLET;ORAL 017851-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Novartis LIORESAL baclofen TABLET;ORAL 017851-003 Jan 20, 1982 ⤷  Sign Up ⤷  Sign Up
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-002 Oct 30, 2003 ⤷  Sign Up ⤷  Sign Up
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-001 Oct 30, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for baclofen

Country Patent Number Title Estimated Expiration
China 109922801 甲硝唑和巴氯芬的混悬剂和稀释剂 (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) ⤷  Sign Up
Canada 3036356 SUSPENSIONS ET DILUANTS POUR LE METRONIDAZOLE ET LE BACLOFENE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) ⤷  Sign Up
European Patent Office 3509592 SUSPENSIONS ET DILUANTS POUR LE MÉTRONIDAZOLE ET LE BACLOFÈNE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) ⤷  Sign Up
Australia 2020323846 Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2021021277 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2018049184 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2023055457 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.